Heborium Group Update on the Signed Letter of Intent With China Health Resources Inc

Phase 1 of due diligence process for the sale of up to 100% of Herborium Group is underway

TEANECK, N.J., March 2, 2012 /PRNewswire/ -- Herborium Group, Inc. (HBRM.PK) www.herborium.com is pleased to announce that the process of Phase 1 due diligence for the sale of up to 100% interest to China Health Resources Inc (OTCBB:CHRI.OB - News) is underway. "We are very excited to advise that the process has begun and is moving along smoothly," stated Dr. Agnes P. Olszewski CEO of Herborium Group

"As we have stated  in our Press Release  of  02/24/2012 regarding a signed Letter of Intent with China Health Resource Inc., both parties have commenced a due diligence process by now.  This process will continue for a duration needed for its completion by both parties.  When this process is completed and the actual transaction takes place, the transaction will be promptly announced. While both parties are truly excited about the opportunity they are also committed to meet their fiduciary responsibilities so the due diligence process is and will be conducted in a most responsible and professional manner.  We are most optimistic of a smooth transaction and final agreement," concluded Dr. Olszewski.   

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals.  The Company uses clinical validation to establish and maintain a differential advantage. The company sales its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com. 

One of our most important responsibilities is to communicate with shareholders in an open and direct manner.  Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends."  We cannot promise future returns.  Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.  The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire: Investorsrelations@herborium.com